Menamed Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.50 M
- Revenue Growth 162.36%
- Profit Growth 317.81%
- Ebitda -245.51%
- Net Worth 952.32%
- Total Assets 217.16%
About Menamed Pharma
Menamed Pharma Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 March 2021 (Three years and 11 months 13 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.50 M.
Shayam Bihari and Vandana Mittal serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100DL2021PTC378001
-
Company No.
378001
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Mar 2021
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Menamed Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shayam Bihari
|
Director | 05-Mar-2021 | Current |
|
Vandana Mittal
|
Director | 05-Mar-2021 | Current |
Financial Performance of Menamed Pharma.
Menamed Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 162.36% increase. The company also saw a substantial improvement in profitability, with a 317.81% increase in profit. The company's net worth Soared by an impressive increase of 952.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Menamed Pharma?
Unlock access to Menamed Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Dec 2022 | State Bank Of India | ₹2.50 M | Open |
How Many Employees Work at Menamed Pharma?
Menamed Pharma has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Menamed Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Menamed Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.